Harnessing ecology to deliver novel, cultured microbial therapies​
TECHNOLOGY
Our team of translational microbiome experts have developed a breakthrough co-culturing platform, Consortiomeâ„¢, that has enabled us to generate an artificial human gut microbial community in a bioreactor.
This enables the development of bespoke therapies with targeted functions to treat disease at a much lower cost than the current donor-derived microbial products.
INVESTMENT
Discover how our unique ecosystem-based approach to drug development is driving BiomeBank’s world-leading co-culturing technology, our portfolio of microbial therapies, and investment opportunities.
PRODUCTS
BiomeBank has a pipeline of therapies in development, including BB265, a rationally designed cultured microbiome therapy engineered for the treatment of Ulcerative Colitis.
The company has a strong track record of commercialisation. Our donor-derived microbiome therapy was the first regulator-approved microbial therapy in the world. We are currently supplying physicians with this product to treat Australian patients with Clostridioides difficile infection.
We are a multidisciplinary team of research scientists and drug development experts who are at the forefront of microbiome research, looking to discover and develop microbiome-based therapies.
The translation of research into the development of innovative and life-saving microbiome-based therapies are further bolstered by BiomeBank’s partnership with world-leading biomedical research organisations. This includes RMIT University, Hudson Institute of Medical Research, and Hospital Networks globally.
BiomeBank's pioneering research has been published in these leading medical journals:
Co-Cultured vs Single Strain Microbial Therapies
Like many thriving ecosystems in nature, diversity is the key ingredient for a healthy gut microbiota. Modern lifestyles and environments are causing gut bacterial diversity to decline, which is associated with the rise of numerous chronic diseases.
To solve this growing problem, BiomeBank is taking a novel ecosystem-based approach to developing our co-culturing Consortiomeâ„¢ technology. Our platform enables us to create unique therapies that harness the power of ecology and technology by combining a consortia of microbes that possess a specific mechanism of action and emergent therapeutic properties that manifest at the community level.
Latest news
BiomeBank has been featured in:
